earnings
confidence high
sentiment positive
materiality 0.80
Lyell Immunopharma Q2 net loss narrows to $42.7M; raises $100M private placement; LYL314 shows 72% CR rate
Lyell Immunopharma, Inc.
2025-Q2 EPS reported
-$6.42
revenue$15,000
- Net loss of $42.7M in Q2 2025 vs $45.8M YoY; non-GAAP net loss $37.8M.
- Private placement up to $100M ($50M initial at $13.32/share); pro-forma cash $347M.
- LYL314 Phase 1/2 data: 88% ORR, 72% CR in 3L+ LBCL; manageable safety; PiNACLE pivotal trial initiated.
- R&D expenses $34.9M (-13% YoY); G&A expenses $9.8M (-20% YoY).
- Phase 3 trial for 2L LBCL expected by early 2026; LYL314 granted RMAT and Fast Track designations.
item 2.02item 9.01